FDA approves Moderna's mRNA flu vaccine for adults 50-64, accelerates senior approval

CNN • 14 août 10h00

The U.S. FDA has approved Moderna's mRNA-based flu vaccine for people aged 50 and older, with standard approval for ages 50-64 and accelerated approval for those 65 and older, pending further study.

Nature • 13 août 15h58

The U.S. FDA has approved Moderna's mRNA-based influenza vaccine, mFLUSIVA, for adults aged 50-64 and granted accelerated approval for those 65 and older, citing trial data showing modest efficacy gains over conventional vaccines.

HuffPost • 11 août 12h17

The U.S. FDA has granted full approval for Moderna's mRNA flu shot, mFlusiva, for adults aged 50-64 and accelerated approval for those 65 and older, citing a 27% higher efficacy than the standard vaccine in trials.

ZME Science • 10 août 23h13

The U.S. Food and Drug Administration has authorized Moderna's mFlusiva, the first mRNA influenza vaccine, after a trial showed it reduced confirmed flu cases compared with a standard-dose shot.

Newsday • 08 août 00h31

The FDA has authorized Moderna's mFlusiva, an mRNA-based influenza shot, for people aged 50 and older, citing a 26.6% higher efficacy than standard flu vaccines, while health officials note that misinformation may limit uptake.

NPR • 06 août 17h06

The U.S. Food and Drug Administration has approved Moderna's mRNA-based seasonal flu shot, mFLU-SIVA, for people aged 50 and older, marking the first flu vaccine using mRNA technology.

Ars Technica • 06 août 16h31

The U.S. Food and Drug Administration has authorized Moderna's mRNA-based influenza vaccine, mFLUSIVA, for use in adults aged 50 and above after advisory committee support and trial data showing strong efficacy and safety.

AP News • 06 août 12h43

The U.S. Food and Drug Administration has approved Moderna's mFlusiva, an mRNA-based influenza vaccine for people aged 50 and up, with full approval for ages 50-64 and accelerated approval for seniors 65 and older.

Engadget • 06 août 08h52

The U.S. Food and Drug Administration has approved Moderna's mRNA flu shot, mFlusiva, for adults aged 50 and older after a Phase 3 trial showed it was more effective than standard-dose vaccines, though it caused more mild to moderate side effects.

Forbes • 06 août 06h44

The U.S. Food and Drug Administration has approved Moderna's mRNA-based influenza vaccine for adults aged 65 and older, marking the first such authorization in the United States.

abcnews.com • 06 août 04h02

The U.S. Food and Drug Administration approved Moderna's mRNA seasonal flu vaccine, mFLUSIVA, for adults 50 and older, citing trial data showing reduced flu cases compared with standard shots.

CBS News • 06 août 03h07

The U.S. FDA has approved Moderna's mRNA-based seasonal flu vaccine, mFLUSIVA, for adults aged 50 and older, marking the first such approval for an influenza vaccine using this technology.

CNN • 06 août 02h33

The U.S. Food and Drug Administration approved Moderna's mRNA-based influenza vaccine for people aged 50 and up, citing a study that showed higher effectiveness than traditional flu shots.

NBC News • 06 août 02h25

The FDA approved Moderna's mFlusiva for adults 50 and older, citing a late-stage trial that showed about 27% higher efficacy than standard flu shots, with the company required to conduct further studies in the oldest age group.